RNAi Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TL;DR
Dr. Zamore's expertise boosts TransCode's RNA-targeted cancer therapy programs, offering a competitive edge in the oncology market.
TransCode Therapeutics appoints Dr. Phillip D. Zamore to its Scientific Advisory Board for his pioneering work in RNA biology and gene silencing mechanisms.
Dr. Zamore's addition to TransCode's Scientific Advisory Board advances RNA-targeted cancer therapy, bringing hope for improved treatment outcomes and patient care.
Joining TransCode's Scientific Advisory Board, Dr. Zamore's groundbreaking research in RNA biology opens doors to new possibilities in cancer treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics has strategically enhanced its scientific capabilities by appointing Dr. Phillip D. Zamore to its Scientific Advisory Board. Dr. Zamore, a renowned RNA interference (RNAi) expert and co-founder of Alnylam Pharmaceuticals, brings extensive expertise in RNA biology and gene silencing mechanisms to the oncology-focused company.
As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Dr. Zamore's election to the National Academy of Sciences underscores his significant contributions to the field. His appointment signals potential advancements in TransCode's RNA therapeutic programs, particularly its lead candidate TTX-MC138, which targets metastatic tumors overexpressing microRNA-10b.
The addition of such a distinguished scientist to the company's advisory board suggests a commitment to innovative cancer treatment strategies. Dr. Zamore's expertise could prove critical in refining TransCode's proprietary TTX nanoparticle platform, which aims to overcome traditional challenges in RNA therapeutic delivery.
TransCode's focus on developing first-in-class RNA therapeutic candidates could benefit significantly from Dr. Zamore's deep understanding of RNA interference and gene silencing techniques. His involvement may accelerate the company's efforts to unlock novel genetic targets for potential cancer treatments.
Curated from InvestorBrandNetwork (IBN)
